ArticleMolecular cancer therapeutics2010

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Daniel A Vallera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.